Canadian-based psychedelic drug manufacturer Optimi Health has signed a CAD 1.2 million (~USD 0.9 million) supply agreement with a private entity engaged in developing mushroom-based therapeutic drugs for pre-clinical research and clinical trials.
As per the agreement, Optimi will cultivate and supply dried Good Manufacturing Practices (GMP) psilocybin-containing biomass and extract to the client's international research sites.
Optimi Health Corp, an end-to-end drug researcher and formulator licensed by Health Canada to produce and supply psychedelic substances and functional mushrooms. They produce psychedelic substances like 3,4-Methylenedioxymethamphetamine and GMP-grade psilocybin, along with functional mushrooms for the health and wellness markets. The company cultivates dried GMP psilocybin-containing biomass and extracts them into refined substances. These substances will be used in the client's research sites.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.